Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 12, 2016, Pages 13730-13741

  Xu, Xiao ^a,c   Liu, Zhikun ^a,b   Wang, Jianguo ^b   Xie, Haiyang ^b   Li, Jie ^b   Cao, Jili ^b   Zhou, Lin ^b   Zheng, Shusen ^a,b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocarcinogenesis; Hepatocellular carcinoma; PARP1

Indexed keywords

GLUTAMATE AMMONIA LIGASE; HEAT SHOCK PROTEIN 70; N MYC DOWNSTREAM REGULATED 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TUMOR MARKER; UNCLASSIFIED DRUG; PARP1 PROTEIN, HUMAN; PROTEOME;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY; CARCINOGENESIS; CASE CONTROL STUDY; FOLLOW UP; LIVER; LIVER TUMOR; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL RATE; TUMOR CELL CULTURE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOMARKERS, TUMOR; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLY (ADP-RIBOSE) POLYMERASE-1; PROGNOSIS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84971639710     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7316     Document Type: Article

References (30)

1. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57:167-185.
2. http://www.nhfpc.gov.cn/jkj/s3582/201307/518216575e544109b2caca07fca3b430.s html (2013).
3. Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res. 2011; 41:405-416.
4. Kim SW, Yang HG, Kang MC, Lee S, Namkoong H, Lee SW, Sung YC. KIAA1114, a full-length protein encoded by the trophinin gene, is a novel surface marker for isolating tumor-initiating cells of multiple hepatocellular carcinoma subtypes. Oncotarget. 2014; 5:1226-1240. doi: 10.18632/oncotarget.1677.
5. Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, Angioni MM, Follenzi A, Quagliata L, Ledda-Columbano GM, Terracciano L, Giordano S, Columbano A. Nrf2, but not beta-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology. 2015; 62:851-862.
6. Chaiteerakij R, Addissie BD, Roberts LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2015; 13:237-245.
7. Jin S, Wang K, Xu K, Xu J, Sun J, Chu Z, Lin D, Koeffler PH, Wang J, Yin D. Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma. Oncotarget. 2014; 5:3685-3696. doi: 10.18632/oncotarget.1986.
8. Friemel J, Rechsteiner M, Frick L, Bohm F, Struckmann K, Egger M, Moch H, Heikenwalder M, Weber A. Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res. 2015; 21:1951-1961.
9. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63:844-855.
10. Yang J, Li J, Dai W, Wang F, Shen M, Chen K, Cheng P,Zhang Y, Wang C, Zhu R, Zhang H, Zheng Y, Wang J, et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis. Exp Ther Med. 2015; 9:1413-1420.
11. Luo Q, Zhang Y, Wang N, Jin G, Jin H, Gu D, Tao X, Huo X, Ge T, Cong W, Wang C, Qin W. Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules. Oncotarget. 2015; 6:6989-6999. doi: 10.18632/oncotarget.3136.
12. Nikolov M, Schmidt C, Urlaub H. Quantitative mass spectrometry-based proteomics: an overview. Methods Mol Biol. 2012; 893:85-100.
13. Xu D, Li Y, Li X, Wei LL, Pan Z, Jiang TT, Chen ZL, Wang C, Cao WM, Zhang X, Ping ZP, Liu CM, Liu JY, et al. Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-dimensional LC-MS/MS. Proteomics. 2015; 15:58-67.
14. Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut. 2011; 60:967-976. doi:10.18632/oncotarget.1677
15. Tremosini S, Forner A, Boix L, Vilana R, Bianchi L, Reig M, Rimola J, Rodriguez-Lope C, Ayuso C, Sole M, Bruix J. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut. 2012; 61:1481-1487.
16. Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, Iavarone M, Colombo M, Jang JJ, Yu E, Jin SY, Morenghi E, Park YN, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009; 50:746-754.
17. Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R, Zhang W, Lv Z, Zheng S, Zhou L. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011; 310:35-45.
18. Lu WJ, Chua MS, So SK. Suppressing N-Myc downstream regulated gene 1 reactivates senescence signaling and inhibits tumor growth in hepatocellular carcinoma. Carcinogenesis. 2014; 35:915-922.
19. Akiba J, Murakami Y, Noda M, Watari K, Ogasawara S, Yoshida T, Kawahara A, Sanada S, Yasumoto M, Yamaguchi R, Kage M, Kuwano M, Ono M, et al. N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase. Cancer Lett. 2011; 310:25-34.
20. Zhang Y, Li Y, Lin C, Ding J, Liao G, Tang B. Aberrant upregulation of 14-3-3sigma and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinoma. PLoS One. 2014; 9:e107251.
21. Gheibi A, Kazemi M, Baradaran A, Akbari M, Salehi M. Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: A potential biomarker for detection of breast cancer in patients. Adv Biomed Res. 2012; 1:80.
22. Qi YJ, Wang M, Liu RM, Wei H, Chao WX, Zhang T, Lou Q, Li XM, Ma J, Zhu H, Yang ZH, Liu HQ, Ma YF. Downregulation of 14-3-3sigma correlates with multistage carcinogenesis and poor prognosis of esophageal squamous cell carcinoma. PLoS One. 2014; 9:e95386.
23. Han G, Fan M, Zhang X. microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem Biophys Res Commun. 2015; 456:804-809.
24. Wang Z, Sun J, Zhao Y, Guo W, Lv K, Zhang Q. Lentivirus-mediated knockdown of tumor protein D52-like 2 inhibits glioma cell proliferation. Cell Mol Biol (Noisy-le-grand). 2014; 60:39-44.
25. Roslan N, Bieche I, Bright RK, Lidereau R, Chen Y, Byrne JA. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog. 2014; 53:807-819.
26. Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa M, Naya Y, Ichikawa T, Seki N. Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 2014; 588:1973-1982.
27. Ko HL, Ren EC. Novel poly (ADP-ribose) polymerase 1 binding motif in hepatitis B virus core promoter impairs DNA damage repair. Hepatology. 2011; 54:1190-1198.
28. Dal Bello B, Rosa L, Campanini N, Tinelli C, Torello Viera F, D'Ambrosio G, Rossi S, Silini EM. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res. 2010; 16:2157-2166.
29. Osada T, Nagashima I, Tsuno NH, Kitayama J, Nagawa H. Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma. J Hepatol. 2000; 33:247-253.
30. Huang C, Wang Y, Liu S, Ding G, Liu W, Zhou J, Kuang M, Ji Y, Kondo T, Fan J. Quantitative Proteomic Analysis Identified Paraoxonase 1 as a Novel Serum Biomarker for Microvascular Invasion in Hepatocellular Carcinoma. J Proteome Res. 2013.